CNSX:VEXT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Vext Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VEXT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.2%

VEXT

-3.4%

CA Pharmaceuticals

2.0%

CA Market


1 Year Return

-75.8%

VEXT

-61.0%

CA Pharmaceuticals

-11.4%

CA Market

Return vs Industry: VEXT underperformed the Canadian Pharmaceuticals industry which returned -60.4% over the past year.

Return vs Market: VEXT underperformed the Canadian Market which returned -11% over the past year.


Shareholder returns

VEXTIndustryMarket
7 Day-3.2%-3.4%2.0%
30 Day-19.3%21.9%4.1%
90 Day-33.3%5.0%-8.8%
1 Year-75.8%-75.8%-61.0%-61.0%-8.3%-11.4%
3 Yearn/a8.4%7.3%-0.2%-9.5%
5 Yearn/a250.7%250.7%15.9%-0.7%

Price Volatility Vs. Market

How volatile is Vext Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vext Science undervalued compared to its fair value and its price relative to the market?

9.41x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VEXT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VEXT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VEXT is poor value based on its PE Ratio (9.2x) compared to the Pharmaceuticals industry average (8.5x).

PE vs Market: VEXT is good value based on its PE Ratio (9.2x) compared to the Canadian market (12.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VEXT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VEXT is good value based on its PB Ratio (1.1x) compared to the CA Pharmaceuticals industry average (1.2x).


Next Steps

Future Growth

How is Vext Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

79.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vext Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vext Science performed over the past 5 years?

-25.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: VEXT has a high level of non-cash earnings.

Growing Profit Margin: VEXT's current net profit margins (12.5%) are lower than last year (20.3%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if VEXT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: VEXT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VEXT had negative earnings growth (-25.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-23.4%).


Return on Equity

High ROE: VEXT's Return on Equity (10.9%) is considered low.


Next Steps

Financial Health

How is Vext Science's financial position?


Financial Position Analysis

Short Term Liabilities: VEXT's short term assets ($24.8M) exceed its short term liabilities ($2.4M).

Long Term Liabilities: VEXT's short term assets ($24.8M) exceed its long term liabilities ($10.7M).


Debt to Equity History and Analysis

Debt Level: VEXT's debt to equity ratio (24.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if VEXT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: VEXT's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: VEXT earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Vext Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VEXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VEXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VEXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VEXT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VEXT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Eric Offenberger

0.33

Tenure

Mr. Eric J. Offenberger has been Chief Executive Officer and Director of Vext Science, Inc. since February 2020. Mr. Offenberger has been the Chief Operating Officer of VEXT since joining the Company in 20 ...


Leadership Team

NamePositionTenureCompensationOwnership
Thai Nguyen
Founder & Executive Chairman0.33yrno datano data
Eric Offenberger
CEO, COO & Director0.33yrno datano data
Denise Lok
Chief Financial Officer0.33yrno datano data
Brian Cameron
Corporate Secretary0.33yrno datano data

0.3yrs

Average Tenure

Experienced Management: VEXT's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thai Nguyen
Founder & Executive Chairman0.33yrno datano data
Eric Offenberger
CEO, COO & Director0.33yrno datano data
David Eaton
Directorno datano data0.36% $138.0k
Matthew Morgan
Member of Advisory Board1.08yrsno datano data
Jonathan Shelton
Directorno datano data0.080% $31.1k
Scott Hill
Member of Advisory Board0.75yrno datano data
Jeffery Yarger
Member of Advisory Board0.67yrno datano data
Caroline Williams
Independent Director0.33yrno datano data

0.5yrs

Average Tenure

Experienced Board: VEXT's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.


Top Shareholders

Company Information

Vext Science, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vext Science, Inc.
  • Ticker: VEXT
  • Exchange: CNSX
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$38.807m
  • Shares outstanding: 84.36m
  • Website: https://www.vapenmj.com

Location

  • Vext Science, Inc.
  • 1055 West Hastings Stree
  • Suite 2250
  • Vancouver
  • British Columbia
  • V6E 2E9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VEXTCNSX (Canadian National Stock Exchange)YesCommon Voting SharesCACADMay 2019
VEXT.FOTCPK (Pink Sheets LLC)YesCommon Voting SharesUSUSDMay 2019
VV5DB (Deutsche Boerse AG)YesCommon Voting SharesDEEURMay 2019

Biography

Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen Brand. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 05:56
End of Day Share Price2020/05/29 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.